Abstract 917: AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancerSylvie M. Guichard, Martin Pass, Zoë Howard et al.|Cancer Research|2012Cited by 17
A Randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCIDavid Adlam, Keith M. Channon, Maciej Zarębiński et al.|International Journal of Cardiology|2021Cited by 16
Characteristics and outcomes of Kaposi sarcoma herpesvirus–associated inflammatory cytokine syndromeRamya Ramaswami, Robert Yarchoan, Stefania Pittaluga et al.|Blood Advances|2025Cited by 12
Kaposi sarcoma herpesvirus viral load as a biomarker for leptomeningeal involvement by primary effusion lymphomaKathryn Lurain, Robert Yarchoan, Ramya Ramaswami et al.|Haematologica|2022Cited by 6
Phase I Study of Lenalidomide Combined with Dose-Adjusted EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma in Participants with or without HIV (NCT02911142)Kathryn Lurain, Robert Yarchoan, Ramya Ramaswami et al.|Blood|2020Cited by 5